96553-53-6

Basic information

• Product Name: (2S,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-ol
• Synonyms: (2S,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-ol
• CAS NO: 96553-53-6
• Molecular Weight: 540.656
• Mol File: 96553-53-6.mol
• Article Data: 162

Chemical Properties

• CAS DataBase Reference: (2S,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-ol(96553-53-6)
• EPA Substance Registry System: (2S,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-ol(96553-53-6)

Safety Data

• Hazardous Substances Data: 96553-53-6(Hazardous Substances Data)

Upstream product

• 134003-35-3 pent-4-enyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside 
• 4132-28-9 2,3,4,6-tetra-O-benzyl-D-mannopyranose 
• 90357-89-4 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl trichloroacetimidate 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 604-69-3 β-D-glucose pentaacetate 
• 99388-26-8 benzyl 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1->4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside 
• 7473-36-1 ethyl 1-thio-β-D-glucopyranoside 
• 32934-24-0 ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside 
• 572-09-8 2,3,4,6-tetra-O-acetyl-D-glucopyranosyl bromide 
• 16758-34-2 1-thiophenyl-β-D-galactopyranoside 
• 78890-61-6 2-methoxyethyl 2,3,4,6-tetra-O-benzyl-β-D-mannopyranoside 
• 157364-81-3 (R/S)-3-buten-2-yl 2,3,4,6-tetra-O-benzyl-β-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 2936-70-1 (2R,3S,4S,5R,6S)-2-Hydroxymethyl-6-phenylsulfanyl-tetrahydro-pyran-3,4,5-triol 

Downstream Products

• 129318-98-5 2,3,4,6-tetra-O-benzyl-1-deoxy-1,1-bis(2-hydroxy-4,5-methylenedioxyphenyl)-D-glucitol 
• 77516-85-9 1-O-(2,4-dinitrophenyl)-2,3,4,6-tetra-O-benzyl-β-D-glucopyranoside 
• 129889-18-5 2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl trifluoroacetate 
• 56632-55-4 cyclohexyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside 
• 193953-69-4 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl diethyl phosphite 
• 58781-27-4 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl 2,3,4,6-tetra-O-benzyl-β-D-glucopyranoside 
• 124064-68-2 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl (phenylsulfate) 
• 124040-40-0 2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl (phenylsulfate) 
• 80726-93-8 2,3,4,6-Tetra-O-benzyl-D-glucosehydrazon 
• 78184-86-8 1,3,4,5-tetra-O-benzyl-α-L-sorbopyranoside 
• 86496-30-2 (2S,3R,4R,5R)-2,3,4,6-tetrakis(benzyloxy)-5-hydroxyhexanal oxime 
• 14233-48-8 2,3,4,6-tetra-O-benzyl-D-glucitol 
• 82110-04-1 (E)-2,4,6-tri-O-benzyl-2-dehydro-3-deoxy-D-erythro-hex-2-enitol 
• 78153-79-4 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl fluoride 

Relevant articles and documents

Formation of and Glycosylation with Per-O-Acetyl Septanosyl Halides: Rationalizing Complex Reactivity En Route to p-Nitrophenyl Septanosides

Protein–carbohydrate interactions are at the heart of many biological processes. For lectins, those interactions result simply in the association of two species, whereas for enzymes like glycosidases, association ultimately leads to cleavage and formation

Beta-D-glucose short-chain fatty acid ester compound as well as preparation method and application thereof

The invention discloses a beta-D-glucose short-chain fatty acid ester compound as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis. The compound is a compound shown as a formula I, or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug of the compound shown as the formula I. The formula is as shown in the description, wherein R is a methyl group, an ethyl group, a propyl group, a propylene group, an isopropylidene group, a butyl group, a butylidene group, an isobutylidene group, an amyl group, a pentylidene group or an isoamylidene group. The compound has potential prevention and treatment effects on diabetes, hyperlipidemia, atherosclerosis, Alzheimer's disease, cardiovascular and cerebrovascular diseases,inflammation, tumors and depression.

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.